Status:
RECRUITING
New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
20-70 years
Brief Summary
In this study, mass spectrometry was used to analyze immune inflammation-related protein complexes, post-translational modified glycopeptide omics and tumor-related metabolomics in serum, respectively...
Detailed Description
Time cohort study: patients with confirmed ovarian epithelial cancer at different time cutoff points before treatment, after surgery, during chemotherapy, and after chemotherapy, until clinically conf...
Eligibility Criteria
Inclusion
- Female
- A diagnosed patient with epithelial ovarian cancer
- Age ≤ 70
Exclusion
- Male
- Suffering from other malignant tumors
- Non-compliant patient
- Age above 70
Key Trial Info
Start Date :
March 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 3 2026
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05410028
Start Date
March 3 2022
End Date
March 3 2026
Last Update
June 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China